TopicCovid drug

Topic: Covid drug

WHO recommends two new Covid drugs, in discussions to secure ‘equitable access’

Mohana Basu - 16 January, 2022

Extent to which Baricitinib & Sotrovimab will save lives depends on how available, affordable they will be, says WHO. New guidelines advise against use of Remdesivir, Ivermectin.

WHO approves Glaxo and Eli Lilly drugs to treat Covid amid Omicron surge

Marthe Fourcade - 14 January, 2022

Eli Lilly’s rheumatoid arthritis drug and GlaxoSmithKline's monoclonal antibody won the WHO nod.

Antiviral Molnupiravir not in govt Covid protocol, but ‘millions of doses’ distributed in a week

Mohana Basu - 7 January, 2022

Pharma companies say doctors working in community settings have begun pre-ordering the drug, several manufacturers gearing up to meet demand.

Scientists launch hunt to find naturally Covid-resistant people, 1,000 volunteers to be enrolled

Sandhya Ramesh - 5 November, 2021

The study looks for people genetically resistant to SARS-CoV-2 virus — if such natural immunity exists. Candidates are one of a couple, where only one partner fell sick, despite close contact.

ICMR drops Ivermectin, Hydroxychloroquine from clinical guidelines for Covid management

ANI - 24 September, 2021

Issuing a set of revised guidelines, ICMR advised that Remedesivir should be used only in select Covid patients and use of Tocilizumab should also be in specific circumstances.

No benefits of Doxycycline found in UK Covid patients, write Oxford researchers in Lancet study

Mohana Basu - 29 July, 2021

According to researchers, the drug that has been commonly used to treat Covid respiratory symptoms does not reduce recovery time, hospital admissions, or deaths related to Covid.

Has Covid exposed limitations of ‘secretive’ ICMR? Some experts think so

Chris Kay - 20 July, 2021

The ICMR has increasingly drawn criticism from India's doctors and scientists, who have questioned its drug recommendations & lack of transparency on data related to variants.

Pharma firms and diagnostics developers need to unite. They are catalysts for saving lives

Radha Rangarajan - 19 July, 2021

Studies of drugs like remdesivir and hydroxychloroquine were underpowered and small, and the results were conflicting and, in many cases, inconclusive.

Molnupiravir helps in faster recovery of mild Covid patients, says Hetero after phase 3 trials

Himani Chandna - 9 July, 2021

Hyderabad-based pharma company, Hetero, announced promising interim results of phase 3 trials and has approached DCGI for emergency use authorisation for the drug in India.

Dr Reddy’s announces commercial launch of Covid drug 2-DG, to cost Rs 990/sachet

PTI - 28 June, 2021

The drug was developed by DRDO in collaboration with Dr Reddy's and granted emergency use approval on 1 May. It will be supplied to major govt and private hospitals across India.

12 Page 1 of 2